{"id":"pitavastatin","rwe":[{"pmid":"41884637","year":"2026","title":"Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort.","finding":"","journal":"Frontiers in cardiovascular medicine","studyType":"Clinical Study"},{"pmid":"41809229","year":"2026","title":"Statin Induced New-onset Diabetes Mellitus - A Narrative Review.","finding":"","journal":"Journal of community hospital internal medicine perspectives","studyType":"Clinical Study"},{"pmid":"41803595","year":"2026","title":"EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk.","finding":"","journal":"Journal of general internal medicine","studyType":"Clinical Study"},{"pmid":"41774493","year":"2026","title":"Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling.","finding":"","journal":"JCI insight","studyType":"Clinical Study"},{"pmid":"41743539","year":"2026","title":"Three-drug combination therapy to prevent glucocorticoid-associated osteonecrosis in patients with systemic lupus erythematosus: a proof-of-concept study.","finding":"","journal":"Therapeutic advances in musculoskeletal disease","studyType":"Clinical Study"}],"_fda":{"id":"48843604-c6e9-1aec-e063-6294a90aea80","set_id":"0f11ee80-871e-4f13-e063-6394a90af19d","openfda":{"unii":["IYD54XEG3W"],"route":["ORAL"],"rxcui":["861643","861648","861652"],"spl_id":["48843604-c6e9-1aec-e063-6294a90aea80"],"brand_name":["Pitavastatin"],"spl_set_id":["0f11ee80-871e-4f13-e063-6394a90af19d"],"package_ndc":["42291-906-90","42291-907-90","42291-905-90"],"product_ndc":["42291-905","42291-906","42291-907"],"generic_name":["PITAVASTATIN CALCIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PITAVASTATIN CALCIUM"],"manufacturer_name":["AvKARE"],"application_number":["ANDA205932"],"original_packager_product_ndc":["0480-3632","0480-3633","0480-3631"]},"version":"2","overdosage":["10 OVERDOSAGE No specific treatment for pitavastatin tablets overdose is known. Contact Poison Control (1-800-222-1222) for latest recommendations. Hemodialysis is unlikely to be of benefit due to high protein binding ratio of pitavastatin tablets."],"description":["11 DESCRIPTION Pitavastatin tablets for oral use is an HMG-CoA reductase inhibitor. The chemical name for pitavastatin is (+)monocalcium bis {(3R, 5S, 6 E )-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}. The structural formula is: The empirical formula for pitavastatin is C 50 H 46 CaF 2 N 2 O 8 and the molecular weight is 880.98. Pitavastatin is odorless and occurs as white to pale-yellow powder. It is freely soluble in pyridine, chloroform, dilute hydrochloric acid, and tetrahydrofuran, soluble in ethylene glycol, sparingly soluble in octanol, slightly soluble in methanol, very slightly soluble in water or ethanol, and practically insoluble in acetonitrile or diethyl ether. Pitavastatin is hygroscopic and slightly unstable in light. Each film-coated tablet of pitavastatin tablets contains 1 mg, 2 mg, or 4 mg of pitavastatin, which is equivalent to 1.045 mg, 2.09 mg, or 4.18 mg, respectively, of pitavastatin calcium and the following inactive ingredients: crospovidone, lactose monohydrate, microcrystalline cellulose, magnesium oxide, magnesium stearate, povidone, sodium starch glycolate, and film coating containing the following inactive ingredients: hypromellose, lactose monohydrate, titanium dioxide, and triacetin. structural formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Pitavastatin tablets for oral administration are provided as white to off-white circular biconvex film-coated tablets that contain 1 mg, 2 mg, or 4 mg of pitavastatin. Each tablet has “OP” debossed on one side and a code number specific to the tablet strength on the other. Packaging Pitavastatin tablets are supplied as: 1 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo “OP” on one side and “57” on the other side. Supplied as follows: NDC 42291-905-90; bottles of 90 tablets 2 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo “OP” on one side and “58” on the other side. Supplied as follows: NDC 42291-906-90; bottles of 90 tablets 4 mg: White to off-white circular biconvex film-coated tablets, debossed with the logo “OP” on one side and “59” on the other side. Supplied as follows: NDC 42291-907-90; bottles of 90 tablets Storage Store at 25°C (77° F), excursions permitted from 15°C-30°C (59°F-86°F). [See USP Controlled Room Temperature]. Protect from light."],"effective_time":"20260116","clinical_studies":["14 CLINICAL STUDIES 14.1 Primary Hyperlipidemia in Adult Study with Atorvastatin (Study 301) Pitavastatin tablets were compared with Atorvastatin Calcium Tablets (referred to as atorvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 817 adult patients with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period and then were randomized to a 12-week treatment with either pitavastatin tablets or atorvastatin (Table 5). Non-inferiority of pitavastatin to a given dose of atorvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 5. For the percent change from baseline to endpoint in LDL-C, pitavastatin tablets were non-inferior to atorvastatin for the two pairwise comparisons: pitavastatin tablets 2 mg vs. atorvastatin 10 mg and pitavastatin tablets 4 mg vs. atorvastatin 20 mg. Mean treatment differences (95% CI) were 0% (-3%, 3%) and 1% (-2%, 4%), respectively. Table 5. Lipid Response by Dose of Pitavastatin Tablets and Atorvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 301 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 2 mg daily 315 -38 -30 -28 -14 4 -35 Pitavastatin Tablets 4 mg daily 298 -45 -35 -32 -19 5 -41 Atorvastatin 10 mg daily 102 -38 -39 -28 -18 3 -35 Atorvastatin 20 mg daily 102 -44 -36 -33 -22 2 -41 Study with Simvastatin (Study 302) Pitavastatin tablets were compared with Simvastatin Tablets (referred to as simvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 843 adult patients with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period and then were randomized to a 12 week treatment with either pitavastatin tablets or simvastatin (Table 6). Non-inferiority of pitavastatin to a given dose of simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 6. For the percent change from baseline to endpoint in LDL-C, pitavastatin tablets were non-inferior to simvastatin for the two pairwise comparisons: pitavastatin tablets 2 mg vs. simvastatin 20 mg and pitavastatin tablets 4 mg vs. simvastatin 40 mg. Mean treatment differences (95% CI) were 4% (1%, 7%) and 1% (-2%, 4%), respectively. Table 6. Lipid Response by Dose of Pitavastatin Tablets and Simvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 302 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 2 mg daily 307 -39 -30 -28 -16 6 -36 Pitavastatin Tablets 4 mg daily 319 -44 -35 -42 -17 6 -41 Simvastatin 20 mg daily 107 -35 -27 -25 -16 6 -32 Simvastatin 40 mg daily 110 -43 -34 -31 -16 7 -39 Study with Pravastatin in Geriatric Patients (Study 306) Pitavastatin tablets were compared with Pravastatin Sodium Tablets (referred to as pravastatin) in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled non-inferiority study of 942 geriatric patients (≥65 years) with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period, and then were randomized to a once daily dose of pitavastatin tablets or pravastatin for 12 weeks (Table 7). Non-inferiority of pitavastatin tablets to a given dose of pravastatin was assumed if the lower bound of the 95% CI for the treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 7. Pitavastatin tablets significantly reduced LDL-C compared to pravastatin as demonstrated by the following pairwise dose comparisons: pitavastatin tablets 1 mg vs. pravastatin 10 mg, pitavastatin tablets 2 mg vs. pravastatin 20 mg and pitavastatin tablets 4 mg vs. pravastatin 40 mg. Mean treatment differences (95% CI) were 9% (6%, 12%), 10% (7%, 13%) and 10% (7%, 13%), respectively. Table 7. Lipid Response by Dose of Pitavastatin Tablets and Pravastatin in Geriatric Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 306 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 1 mg daily 207 -31 -25 -22 -13 1 -29 Pitavastatin Tablets 2 mg daily 224 -39 -31 -27 -15 2 -36 Pitavastatin Tablets 4 mg daily 210 -44 -37 -31 -22 4 -41 Pravastatin 10 mg daily 103 -22 -17 -15 -5 0 -20 Pravastatin 20 mg daily 96 -29 -22 -21 -11 -1 -27 Pravastatin 40 mg daily 102 -34 -28 -24 -15 1 -32 Study with Simvastatin in Patients with ≥ 2 Risk Factors for Coronary Heart Disease (Study 304) Pitavastatin tablets were compared with Simvastatin Tablets (referred to as simvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 351 adult patients with primary hyperlipidemia or mixed dyslipidemia with ≥2 risk factors for coronary heart disease. After a 6- to 8-week wash-out/dietary lead-in period, patients were randomized to a 12-week treatment with either pitavastatin tablets or simvastatin (Table 8). Non-inferiority of pitavastatin tablets to simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 8. Pitavastatin tablets 4 mg was non-inferior to simvastatin 40 mg for percent change from baseline to endpoint in LDL-C. The mean treatment difference (95% CI) was 0% (-2%, 3%). Table 8. Lipid Response by Dose of Pitavastatin Tablets and Simvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia with ≥2 Risk Factors for Coronary Heart Disease in Study 304 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 4 mg daily 233 -44 -34 -31 -20 7 -40 Simvastatin 40 mg daily 118 -44 -34 -31 -15 5 -39 Study with Atorvastatin in Patients with Type 2 Diabetes Mellitus (Study 305) Pitavastatin tablets were compared with Atorvastatin Calcium Tablets (referred to as atorvastatin) in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled, non-inferiority study of 410 adult patients with type 2 diabetes mellitus and mixed dyslipidemia. Patients entered a 6- to 8-week washout/dietary lead-in period and were randomized to a once daily dose of pitavastatin tablets or atorvastatin for 12 weeks. Non-inferiority of pitavastatin tablets was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 9. The treatment difference (95% CI) for LDL-C percent change from baseline was -2% (-6.2%, 1.5%). The two treatment groups were not statistically different on LDL-C. However, the lower limit of the CI was -6.2%, slightly exceeding the -6% non-inferiority limit. The study failed to demonstrate that pitavastatin tablets were not significantly different than atorvastatin in lowering LDL-C in patients with type 2 diabetes mellitus and mixed dyslipidemia. Table 9. Lipid Response by Dose of Pitavastatin Tablets and Atorvastatin in Adult Patients with Type 2 Diabetes Mellitus and Mixed Dyslipidemia in Study 305 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 4 mg daily 274 -41 -32 -28 -20 7 -36 Atorvastatin 20 mg daily 136 -43 -34 -32 -27 8 -40 The treatment differences in efficacy in LDL-C change from baseline between pitavastatin tablets and active controls (i.e., atorvastatin, simvastatin, or pravastatin) in the active-controlled studies described above are summarized in Figure 1. Figure 1. Treatment Difference in Adjusted Mean Percent Change in LDL-C between Pitavastatin Tablets and the Comparator (Atorvastatin, Simvastatin, or Pravastatin) Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. figure 1","14.1 Primary Hyperlipidemia in Adult Study with Atorvastatin (Study 301) Pitavastatin tablets were compared with Atorvastatin Calcium Tablets (referred to as atorvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 817 adult patients with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period and then were randomized to a 12-week treatment with either pitavastatin tablets or atorvastatin (Table 5). Non-inferiority of pitavastatin to a given dose of atorvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 5. For the percent change from baseline to endpoint in LDL-C, pitavastatin tablets were non-inferior to atorvastatin for the two pairwise comparisons: pitavastatin tablets 2 mg vs. atorvastatin 10 mg and pitavastatin tablets 4 mg vs. atorvastatin 20 mg. Mean treatment differences (95% CI) were 0% (-3%, 3%) and 1% (-2%, 4%), respectively. Table 5. Lipid Response by Dose of Pitavastatin Tablets and Atorvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 301 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 2 mg daily 315 -38 -30 -28 -14 4 -35 Pitavastatin Tablets 4 mg daily 298 -45 -35 -32 -19 5 -41 Atorvastatin 10 mg daily 102 -38 -39 -28 -18 3 -35 Atorvastatin 20 mg daily 102 -44 -36 -33 -22 2 -41 Study with Simvastatin (Study 302) Pitavastatin tablets were compared with Simvastatin Tablets (referred to as simvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 843 adult patients with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period and then were randomized to a 12 week treatment with either pitavastatin tablets or simvastatin (Table 6). Non-inferiority of pitavastatin to a given dose of simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 6. For the percent change from baseline to endpoint in LDL-C, pitavastatin tablets were non-inferior to simvastatin for the two pairwise comparisons: pitavastatin tablets 2 mg vs. simvastatin 20 mg and pitavastatin tablets 4 mg vs. simvastatin 40 mg. Mean treatment differences (95% CI) were 4% (1%, 7%) and 1% (-2%, 4%), respectively. Table 6. Lipid Response by Dose of Pitavastatin Tablets and Simvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 302 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 2 mg daily 307 -39 -30 -28 -16 6 -36 Pitavastatin Tablets 4 mg daily 319 -44 -35 -42 -17 6 -41 Simvastatin 20 mg daily 107 -35 -27 -25 -16 6 -32 Simvastatin 40 mg daily 110 -43 -34 -31 -16 7 -39 Study with Pravastatin in Geriatric Patients (Study 306) Pitavastatin tablets were compared with Pravastatin Sodium Tablets (referred to as pravastatin) in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled non-inferiority study of 942 geriatric patients (≥65 years) with primary hyperlipidemia or mixed dyslipidemia. Patients entered a 6- to 8-week wash-out/dietary lead-in period, and then were randomized to a once daily dose of pitavastatin tablets or pravastatin for 12 weeks (Table 7). Non-inferiority of pitavastatin tablets to a given dose of pravastatin was assumed if the lower bound of the 95% CI for the treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 7. Pitavastatin tablets significantly reduced LDL-C compared to pravastatin as demonstrated by the following pairwise dose comparisons: pitavastatin tablets 1 mg vs. pravastatin 10 mg, pitavastatin tablets 2 mg vs. pravastatin 20 mg and pitavastatin tablets 4 mg vs. pravastatin 40 mg. Mean treatment differences (95% CI) were 9% (6%, 12%), 10% (7%, 13%) and 10% (7%, 13%), respectively. Table 7. Lipid Response by Dose of Pitavastatin Tablets and Pravastatin in Geriatric Patients with Primary Hyperlipidemia or Mixed Dyslipidemia in Study 306 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 1 mg daily 207 -31 -25 -22 -13 1 -29 Pitavastatin Tablets 2 mg daily 224 -39 -31 -27 -15 2 -36 Pitavastatin Tablets 4 mg daily 210 -44 -37 -31 -22 4 -41 Pravastatin 10 mg daily 103 -22 -17 -15 -5 0 -20 Pravastatin 20 mg daily 96 -29 -22 -21 -11 -1 -27 Pravastatin 40 mg daily 102 -34 -28 -24 -15 1 -32 Study with Simvastatin in Patients with ≥ 2 Risk Factors for Coronary Heart Disease (Study 304) Pitavastatin tablets were compared with Simvastatin Tablets (referred to as simvastatin) in a randomized, multicenter, double-blind, double-dummy, active-controlled, non-inferiority study of 351 adult patients with primary hyperlipidemia or mixed dyslipidemia with ≥2 risk factors for coronary heart disease. After a 6- to 8-week wash-out/dietary lead-in period, patients were randomized to a 12-week treatment with either pitavastatin tablets or simvastatin (Table 8). Non-inferiority of pitavastatin tablets to simvastatin was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 8. Pitavastatin tablets 4 mg was non-inferior to simvastatin 40 mg for percent change from baseline to endpoint in LDL-C. The mean treatment difference (95% CI) was 0% (-2%, 3%). Table 8. Lipid Response by Dose of Pitavastatin Tablets and Simvastatin in Adult Patients with Primary Hyperlipidemia or Mixed Dyslipidemia with ≥2 Risk Factors for Coronary Heart Disease in Study 304 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 4 mg daily 233 -44 -34 -31 -20 7 -40 Simvastatin 40 mg daily 118 -44 -34 -31 -15 5 -39 Study with Atorvastatin in Patients with Type 2 Diabetes Mellitus (Study 305) Pitavastatin tablets were compared with Atorvastatin Calcium Tablets (referred to as atorvastatin) in a randomized, multicenter, double-blind, double-dummy, parallel group, active-controlled, non-inferiority study of 410 adult patients with type 2 diabetes mellitus and mixed dyslipidemia. Patients entered a 6- to 8-week washout/dietary lead-in period and were randomized to a once daily dose of pitavastatin tablets or atorvastatin for 12 weeks. Non-inferiority of pitavastatin tablets was considered to be demonstrated if the lower bound of the 95% CI for the mean treatment difference was greater than -6% for the mean percent change in LDL-C. Lipid results are shown in Table 9. The treatment difference (95% CI) for LDL-C percent change from baseline was -2% (-6.2%, 1.5%). The two treatment groups were not statistically different on LDL-C. However, the lower limit of the CI was -6.2%, slightly exceeding the -6% non-inferiority limit. The study failed to demonstrate that pitavastatin tablets were not significantly different than atorvastatin in lowering LDL-C in patients with type 2 diabetes mellitus and mixed dyslipidemia. Table 9. Lipid Response by Dose of Pitavastatin Tablets and Atorvastatin in Adult Patients with Type 2 Diabetes Mellitus and Mixed Dyslipidemia in Study 305 (Mean % Change from Baseline at Week 12) Treatment N LDL-C Apo-B TC TG HDL-C non-HDL-C Pitavastatin Tablets 4 mg daily 274 -41 -32 -28 -20 7 -36 Atorvastatin 20 mg daily 136 -43 -34 -32 -27 8 -40 The treatment differences in efficacy in LDL-C change from baseline between pitavastatin tablets and active controls (i.e., atorvastatin, simvastatin, or pravastatin) in the active-controlled studies described above are summarized in Figure 1. Figure 1. Treatment Difference in Adjusted Mean Percent Change in LDL-C between Pitavastatin Tablets and the Comparator (Atorvastatin, Simvastatin, or Pravastatin) Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. figure 1"],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are discussed in other sections of the labeling: Myopathy and Rhabdomyolysis [see Warnings and Precautions ( 5.1 )] Immune-Mediated Necrotizing Myopathy [see Warning and Precautions ( 5.2 )] Hepatic Dysfunction [see Warning and Precautions ( 5.3 )] Increases in HbA1c and Fasting Serum Glucose Levels [see Warning and Precautions ( 5.4 )]. The most frequent adverse reactions (rate ≥2%) were myalgia, constipation, back pain, diarrhea, and pain in extremity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of one drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Adults with Primary Hyperlipidemia In 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 adult patients with primary hyperlipidemia were administered pitavastatin tablets 1 mg to 4 mg daily. The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks). The mean age of the patients was 60.9 years (range; 18 years – 89 years) and 52% were females. Approximately 93% of the patients were White, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other. In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin tablets -treated patients were discontinued due to adverse reactions. The most common adverse reactions that led to treatment discontinuation were: elevated creatine phosphokinase (0.6% on 4 mg) and myalgia (0.5% on 4 mg). Adverse reactions reported in ≥ 2% of patients in controlled clinical studies and at a rate greater than or equal to placebo are shown in Table 1. These studies had treatment duration of up to 12 weeks. Table 1. Adverse Reactions ( ≥ 2% and ≥ placebo) in Adults with Primary Hyperlipidemia in Studies up to 12 Weeks Adverse Reactions Placebo (n= 208) % Pitavastatin Tablets 1 mg (n=309) % Pitavastatin Tablets 2 mg (n=951) % Pitavastatin Tablets 4 mg (n=1540) % Myalgia 1.4 1.9 2.8 3.1 Constipation 1.9 3.6 1.5 2.2 Diarrhea 1.9 2.6 1.5 1.9 Back Pain 2.9 3.9 1.8 1.4 Pain in extremity 1.9 2.3 0.6 0.9 Other adverse reactions reported from clinical studies were arthralgia, headache, influenza, and nasopharyngitis. Hypersensitivity reactions including rash, pruritus, and urticaria have been reported with Pitavastatin tablets. The following laboratory abnormalities have been reported: elevated creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin, and glucose. Adverse Reactions in Adult HIV-Infected Patients with Dyslipidemia In a double-blind, randomized, controlled, 52-week trial, 252 HIV-infected patients with dyslipidemia were treated with either pitavastatin tablets 4mg once daily (n=126) or another statin (n=126). All patients were taking antiretroviral therapy (excluding darunavir) and had HIV-1 RNA less than 200 copies/mL and CD4 count greater than 200 cell/μL for at least 3 months prior to randomization. The safety profile of pitavastatin tablets was generally consistent with that observed in the clinical trials described above. One patient (0.8%) treated with pitavastatin tablets had a peak creatine phosphokinase value exceeding 10 times the upper limit of normal (ULN), which resolved spontaneously. Four patients (3%) treated with pitavastatin tablets had at least one ALT value exceeding 3 times but less than 5 times the ULN, none of which led to drug discontinuation. Virologic failure was reported for four patients (3%) treated with pitavastatin tablets, defined as a confirmed measurement of HIV-1 RNA exceeding 200 copies/mL that was also more than a 2-fold increase from baseline. Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of pitavastatin tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disorders: abdominal discomfort, abdominal pain, dyspepsia, nausea General disorders: asthenia, fatigue, malaise, dizziness Hepatobiliary disorders: hepatitis, jaundice, fatal and non-fatal hepatic failure Immune system disorders: angioedema, immune-mediated necrotizing myopathy associated with statin use. Metabolism and nutrition disorders: increases in HbA1c, fasting serum glucose levels Musculoskeletal and connective tissue disorders: muscle spasms, myopathy, rhabdomyolysis Nervous system disorders: hypoesthesia, peripheral neuropathy Psychiatric disorders: insomnia, depression. Rare reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. Cognitive impairment was generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). Reproductive system and breast disorders: erectile dysfunction Respiratory, thoracic and mediastinal disorders: interstitial lung disease Skin and subcutaneous tissue disorders: lichen planus To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["4 CONTRAINDICATIONS Pitavastatin tablets are contraindicated in the following conditions: Concomitant use of cyclosporine [see Drug Interactions ( 7 )] . Acute liver failure or decompensated cirrhosis [see Warning and Precautions ( 5.3 )]. Hypersensitivity to pitavastatin or any excipients in pitavastatin tablets. Hypersensitivity reactions including angioedema, rash, pruritus, and urticaria have been reported with pitavastatin tablets [see Adverse Reactions ( 6 )] . Cyclosporine ( 4 , 7 ) Active liver failure or decompensated cirrhosis ( 4 , 5.3 ) Hypersensitivity to pitavastatin or any excipients in pitavastatin tablets ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Table 2 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when administered concomitantly with pitavastatin tablets and instructions for preventing or managing drug interactions [see Warnings and Precautions ( 5.1 ), Clinical Pharmacology ( 12.3 )]. Table 2. Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with pitavastatin tablets Cyclosporine Clinical Impact: Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Intervention: Concomitant use of cyclosporine with pitavastatin tablets is contraindicated [see Contraindications ( 4 )]. Gemfibrozil Clinical Impact: Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including pitavastatin tablets. Intervention: Avoid concomitant use of gemfibrozil with pitavastatin tablets. Erythromycin Clinical Impact: Erythromycin significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Intervention: In patients taking erythromycin, do not exceed pitavastatin tablets 1 mg once daily [see Dosage and Administration ( 2.4 )]. Rifampin Clinical Impact: Rifampin significantly increases peak pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis. Intervention: In patients taking rifampin, do not exceed pitavastatin tablets 2 mg once daily [see Dosage and Administration ( 2.4 )]. Fibrates Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins, including pitavastatin tablets. Intervention: Consider if the benefit of using fibrates concomitantly with pitavastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. Niacin Clinical Impact: The risk of myopathy and rhabdomyolysis may be increased with concomitant use of lipid-modifying doses (≥1 g/day) of niacin with pitavastatin tablets. Intervention: Consider if the benefit of using lipid-modifying doses (≥1 g/day) of niacin concomitantly with pitavastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with statins, including pitavastatin tablets. Intervention: Consider the risk/benefit of concomitant use of colchicine with pitavastatin tablets. See full prescribing information for details regarding concomitant use of pitavastatin tablets with other drugs that increase the risk of myopathy and rhabdomyolysis. ( 2.4 , 7 )"],"recent_major_changes":["Contraindications, Pregnancy and Lactation ( 4 ) Removed 03/2023 Warnings and Precautions, Immune-Mediated Necrotizing Myopathy ( 5.2 ) 03/2023"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very low density lipoproteins. 12.2 Pharmacodynamics Cardiac Electrophysiology In a randomized, double-blind, placebo-controlled, 4-way parallel, active-comparator study with moxifloxacin in 174 healthy participants, pitavastatin tablets were not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum dose of 4 mg daily). 12.3 Pharmacokinetics Absorption Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration. Both C max and AUC 0-inf increased in an approximately dose-proportional manner for single pitavastatin tablets doses from 1 mg to 24 mg once daily. The absolute bioavailability of pitavastatin oral solution is 51%. The C max and AUC of pitavastatin did not differ following evening or morning drug administration. In healthy volunteers receiving 4 mg pitavastatin, the percent change from baseline for LDL-C following evening dosing was slightly greater than that following morning dosing. Pitavastatin was absorbed in the small intestine but very little in the colon. Effect of Food Administration of pitavastatin tablets with a high fat meal (50% fat content) decreases pitavastatin C max by 43% but does not significantly reduce pitavastatin AUC. Distribution Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L. Elimination Metabolism The principal route of pitavastatin metabolism is glucuronidation via liver uridine 5'-diphosphate glucuronosyltransferase (UGT) with subsequent formation of pitavastatin lactone. There is only minimal metabolism by the cytochrome P450 system. Pitavastatin is marginally metabolized by CYP2C9 and to a lesser extent by CYP2C8. The major metabolite in human plasma is the lactone, which is formed via an ester-type pitavastatin glucuronide conjugate by UGTs (UGT1A3 and UGT2B7). Excretion A mean of 15% of radioactivity of orally administered, single 32 mg 14 C-labeled pitavastatin dose was excreted in urine, whereas a mean of 79% of the dose was excreted in feces within 7 days. The mean plasma elimination half-life is approximately 12 hours. Specific Populations Geriatric Patients In a pharmacokinetic study which compared healthy young and geriatric (≥65 years) volunteers, pitavastatin C max and AUC were 10 and 30% higher, respectively, in the geriatric patients [see Use in Specific Populations ( 8.5 )] Pediatric Patients Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. Male and Female Patients In a pharmacokinetic study, which compared healthy male and female volunteers, pitavastatin C max and AUC were 60 and 54% higher, respectively in females. Racial or Ethnic Groups In pharmacokinetic studies pitavastatin C max and AUC were 21 and 5% lower, respectively in Black or African American healthy volunteers compared with those of White healthy volunteers. In pharmacokinetic comparison between White volunteers and Japanese volunteers, there were no significant differences in C max and AUC. Patients with Renal Impairment In patients with moderate renal impairment (estimated glomerular filtration rate of 30 – 59 mL/min/1.73 m 2 ) and end stage renal disease receiving hemodialysis, pitavastatin AUC 0-inf is 102% and 86% higher than those of healthy volunteers, respectively, while pitavastatin C max is 60% and 40% higher than those of healthy volunteers, respectively. Patients received hemodialysis immediately before pitavastatin dosing and did not undergo hemodialysis during the pharmacokinetic study. Hemodialysis patients have 33% and 36% increases in the mean unbound fraction of pitavastatin as compared to healthy volunteers and patients with moderate renal impairment, respectively [see Use in Specific Populations ( 8.6 )]. In another pharmacokinetic study, patients with severe renal impairment (estimated glomerular filtration rate 15 – 29 mL/min/1.73 m 2 ) not receiving hemodialysis were administered a single dose of pitavastatin tablets 4 mg. The AUC 0-inf and the C max were 36% and 18% higher, respectively, compared with those of healthy volunteers. For both patients with severe renal impairment and healthy volunteers, the mean percentage of protein-unbound pitavastatin was approximately 0.6% [see Use in Specific Populations ( 8.6 )]. The effect of mild renal impairment on pitavastatin exposure has not been studied. Patients with Hepatic Impairment The disposition of pitavastatin was compared in healthy volunteers and patients with various degrees of hepatic impairment. Pitavastatin C max and AUC inf in patients with moderate hepatic impairment (Child-Pugh B disease) was 2.7-fold and 3.8-fold higher, respectively as compared to healthy volunteers. In patients with mild hepatic impairment (Child-Pugh A disease), pitavastatin C max and AUC inf were 30% and 60% higher as compared to healthy volunteers. Mean pitavastatin half-life for moderate hepatic impairment, mild hepatic impairment, and healthy volunteers were 15, 10, and 8 hours, respectively [see Contraindications ( 4 ), Warnings and Precautions ( 5.3 )]. Drug Interaction Studies Warfarin The steady-state pharmacodynamics (international normalized ratio [INR] and prothrombin time [PT]) and pharmacokinetics of warfarin in healthy volunteers were unaffected by the coadministration of pitavastatin tablets 4 mg daily. Table 3 presents the effect of coadministered drugs on pitavastatin systemic exposure: Table 3. Effect of Coadministered Drugs on Pitavastatin Systemic Exposure Coadministered drug Dosage regimen Change in AUC* Change in C max * Cyclosporine Pitavastatin 2 mg QD for 6 days + cyclosporine 2 mg/kg on Day 6 ↑ 4.6 fold † ↑ 6.6 fold † Erythromycin Pitavastatin 4 mg single dose on Day 4 + erythromycin 500 mg 4 times daily for 6 days ↑ 2.8 fold † ↑ 3.6 fold † Rifampin Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days ↑ 29% ↑ 2.0 fold † Atazanavir Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days ↑ 31% ↑ 60% Darunavir/Ritonavir Pitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800 mg/100 mg QD on Days 6-16 ↓ 26% ↓ 4% Lopinavir/Ritonavir Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24 ↓ 20% ↓ 4 % Gemfibrozil Pitavastatin 4 mg QD + gemfibrozil 600 mg BID for 7 days ↑ 45% ↑ 31% Fenofibrate Pitavastatin 4 mg QD + fenofibrate 160 mg QD for 7 days ↑ 18% ↑ 11% Ezetimibe Pitavastatin 2 mg QD + ezetimibe 10 mg for 7 days ↓ 2% ↓ 0.2% Enalapril Pitavastatin 4 mg QD + enalapril 20 mg daily for 5 days ↑ 6% ↓ 7% Digoxin Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days ↑ 4% ↓ 9% Diltiazem LA Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15 ↑ 10% ↑ 15% Grapefruit Juice Pitavastatin 2 mg single dose on Day 3 + grapefruit juice for 4 days ↑ 15% ↓ 12% Itraconazole Pitavastatin 4 mg single dose on Day 4 + itraconazole 200 mg daily for 5 days ↓ 23% ↓ 22% * Data presented as x-fold change represent the ratio between coadministration and pitavastatin alone (i.e., 1-fold = no change). Data presented as % change represent % difference relative to pitavastatin alone (i.e., 0% = no change). † Considered clinically significant [see Dosage and Administration ( 2.4 ), Drug Interactions ( 7 )] BID = twice daily; QD = once daily; LA = Long Acting Table 4 presents the effect of pitavastatin coadministration on systemic exposure of other drugs: Table 4. Effect of Pitavastatin Coadministration on Systemic Exposure to Other Drugs Coadministered drug Dosage regimen Change in AUC* Change in C max * Atazanavir Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days ↑ 6% ↑ 13% Darunavir Pitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800 mg/100 mg QD on Days 6-16 ↑ 3% ↑ 6% Lopinavir Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24 ↓ 9% ↓ 7% Ritonavir Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24 ↓ 11% ↓ 11% Ritonavir Pitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800 mg/100 mg QD on Days 6-16 ↑ 8% ↑ 2% Enalapril Pitavastatin 4 mg QD + enalapril 20 mg daily for 5 days Enalapril ↑ 12% ↑ 12% Enalaprilat ↓ 1% ↓ 1% Warfarin Individualized maintenance dose of warfarin (2-7 mg) for 8 days + pitavastatin 4 mg QD for 9 days R-warfarin ↑ 7% ↑ 3% S-warfarin ↑ 6% ↑ 3% Ezetimibe Pitavastatin 2 mg QD + ezetimibe 10 mg for 7 days ↑ 9% ↑ 2% Digoxin Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days ↓ 3% ↓ 4% Diltiazem LA Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15 ↓ 2% ↓ 7% Rifampin Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days ↓ 15% ↓ 18% *Data presented as % change represent % difference relative to the investigated drug alone (i.e., 0% = no change). BID = twice daily; QD = once daily; LA = Long Acting"],"indications_and_usage":["1 INDICATIONS AND USAGE Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. Pitavastatin is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: ( 1 ) Adult patients with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH)."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, renal impairment, uncontrolled hypothyroidism, concomitant use with certain other drugs, and higher doses of pitavastatin tablets. Discontinue pitavastatin tablets if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever ( 5.1 , 7 , 8.5 , 8.6 ). Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported. Discontinue pitavastatin tablets if IMNM is suspected ( 5.2 ). Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzyme before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue pitavastatin tablets ( 5.3 ) 5.1 Myopathy and Rhabdomyolysis Pitavastatin tablets may cause myopathy (muscle pain, tenderness, or weakness with elevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statin, including pitavastatin tablets. Risk Factors for Myopathy Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use of certain drugs (including other lipidlowering therapies), and higher pitavastatin tablets dosage [see Dosage and Administration ( 2.2 ), Drug Interactions ( 7 ), and Use in Specific Populations ( 8.5 , 8.6 )]. Dosages of pitavastatin tablets greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. The maximum recommended dose of pitavastatin tablets is 4 mg once daily . Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis Pitavastatin tablets are contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil [see Contraindications ( 4 ) and Drug Interactions ( 7 )]. There are pitavastatin tablets dosage restrictions for patients taking erythromycin or rifampin [see Dosage and Administration ( 2.4 )]. The following drugs when used concomitantly with pitavastatin tablets may also increase the risk of myopathy and rhabdomyolysis: lipid-modifying dosages of niacin (>1grams/day), fibrates, and colchicine [see Drug Interactions ( 7 )]. Discontinue pitavastatin tablets if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve if pitavastatin tablets are discontinued. Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis, (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy). Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. 5.2 Immune-Mediated Necrotizing Myopathy There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue pitavastatin tablets if IMNM is suspected. 5.3 Hepatic Dysfunction Increases in serum transaminases have been reported with pitavastatin tablets [see Adverse Reactions ( 6 )]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including pitavastatin tablets. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury. Consider liver enzyme testing before the initiation of pitavastatin tablets and when clinically indicated thereafter. Pitavastatin tablets are contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications ( 4 )]. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue pitavastatin tablets. 5.4 Increases in HbA1c and Fasting Serum Glucose Levels Increases in HbA1c and fasting serum glucose levels have been reported with statins, including pitavastatin tablets. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices."],"clinical_studies_table":["
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 2 mg daily 315-38-30-28-144-35
Pitavastatin Tablets 4 mg daily 298-45-35-32-195-41
Atorvastatin 10 mg daily 102-38-39-28-183-35
Atorvastatin 20 mg daily 102-44-36-33-222-41
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 2 mg daily 307-39-30-28-166-36
Pitavastatin Tablets 4 mg daily 319-44-35-42-176-41
Simvastatin 20 mg daily 107-35-27-25-166-32
Simvastatin 40 mg daily 110-43-34-31-167-39
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 1 mg daily 207-31-25-22-131-29
Pitavastatin Tablets 2 mg daily 224-39-31-27-152-36
Pitavastatin Tablets 4 mg daily 210-44-37-31-224-41
Pravastatin 10 mg daily 103-22-17-15-50-20
Pravastatin 20 mg daily 96-29-22-21-11-1-27
Pravastatin 40 mg daily 102-34-28-24-151-32
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 4 mg daily 233-44-34-31-207-40
Simvastatin 40 mg daily 118-44-34-31-155-39
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 4 mg daily 274-41-32-28-207-36
Atorvastatin 20 mg daily 136-43-34-32-278-40
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 2 mg daily 315-38-30-28-144-35
Pitavastatin Tablets 4 mg daily 298-45-35-32-195-41
Atorvastatin 10 mg daily 102-38-39-28-183-35
Atorvastatin 20 mg daily 102-44-36-33-222-41
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 2 mg daily 307-39-30-28-166-36
Pitavastatin Tablets 4 mg daily 319-44-35-42-176-41
Simvastatin 20 mg daily 107-35-27-25-166-32
Simvastatin 40 mg daily 110-43-34-31-167-39
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 1 mg daily 207-31-25-22-131-29
Pitavastatin Tablets 2 mg daily 224-39-31-27-152-36
Pitavastatin Tablets 4 mg daily 210-44-37-31-224-41
Pravastatin 10 mg daily 103-22-17-15-50-20
Pravastatin 20 mg daily 96-29-22-21-11-1-27
Pravastatin 40 mg daily 102-34-28-24-151-32
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 4 mg daily 233-44-34-31-207-40
Simvastatin 40 mg daily 118-44-34-31-155-39
","
TreatmentNLDL-CApo-BTCTGHDL-Cnon-HDL-C
Pitavastatin Tablets 4 mg daily 274-41-32-28-207-36
Atorvastatin 20 mg daily 136-43-34-32-278-40
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 92-week carcinogenicity study in mice given pitavastatin, at the maximum tolerated dose of 75 mg/kg/day with systemic maximum exposures (AUC) 26 times the clinical maximum exposure at 4 mg daily, there was an absence of drug-related tumors. In a 92-week carcinogenicity study in rats given pitavastatin at 1, 5, 25 mg/kg/day by oral gavage there was a significant increase in the incidence of thyroid follicular cell tumors at 25 mg/kg/day, which represents 295 times human systemic exposures based on AUC at the 4 mg daily maximum human dose. In a 26-week transgenic mouse (Tg rasH2) carcinogenicity study where animals were given pitavastatin at 30, 75, and 150 mg/kg/day by oral gavage, no clinically significant tumors were observed. Pitavastatin was not mutagenic in the Ames test with Salmonella typhimurium and Escherichia coli with and without metabolic activation, the micronucleus test following a single administration in mice and multiple administrations in rats, the unscheduled DNA synthesis test in rats, and a Comet assay in mice. In the chromosomal aberration test, clastogenicity was observed at the highest doses tested, which also elicited high levels of cytotoxicity. Pitavastatin had no adverse effects on male and female rat fertility at oral doses of 10 and 30 mg/kg/day, respectively, at systemic exposures 56- and 354-times clinical exposure at 4 mg daily based on AUC. Pitavastatin treatment in rabbits resulted in mortality in males and females given 1 mg/kg/day (30-times clinical systemic exposure at 4 mg daily based on AUC) and higher during a fertility study. Although the cause of death was not determined, rabbits had gross signs of renal toxicity (kidneys whitened) indicative of possible ischemia. Lower doses (15-times human systemic exposure) did not show significant toxicity in adult males and females. However, decreased implantations, increased resorptions, and decreased viability of fetuses were observed."],"adverse_reactions_table":["
Adverse Reactions Placebo (n= 208) % Pitavastatin Tablets 1 mg (n=309) % Pitavastatin Tablets 2 mg (n=951) % Pitavastatin Tablets 4 mg (n=1540) %
Myalgia1.41.92.83.1
Constipation1.93.61.52.2
Diarrhea1.92.61.51.9
Back Pain2.93.91.81.4
Pain in extremity1.92.30.60.9
"],"drug_interactions_table":["
Cyclosporine
Clinical Impact:Cyclosporine significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.
Intervention:Concomitant use of cyclosporine with pitavastatin tablets is contraindicated [see Contraindications (4)].
Gemfibrozil
Clinical Impact:Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including pitavastatin tablets.
Intervention:Avoid concomitant use of gemfibrozil with pitavastatin tablets.
Erythromycin
Clinical Impact:Erythromycin significantly increases pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.
Intervention:In patients taking erythromycin, do not exceed pitavastatin tablets 1 mg once daily [see Dosage and Administration (2.4)].
Rifampin
Clinical Impact:Rifampin significantly increases peak pitavastatin exposure and increases the risk of myopathy and rhabdomyolysis.
Intervention:In patients taking rifampin, do not exceed pitavastatin tablets 2 mg once daily [see Dosage and Administration (2.4)].
Fibrates
Clinical Impact:Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins, including pitavastatin tablets.
Intervention:Consider if the benefit of using fibrates concomitantly with pitavastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis.
Niacin
Clinical Impact:The risk of myopathy and rhabdomyolysis may be increased with concomitant use of lipid-modifying doses (≥1 g/day) of niacin with pitavastatin tablets.
Intervention:Consider if the benefit of using lipid-modifying doses (≥1 g/day) of niacin concomitantly with pitavastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis.
Colchicine
Clinical Impact:Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with statins, including pitavastatin tablets.
Intervention:Consider the risk/benefit of concomitant use of colchicine with pitavastatin tablets.
"],"spl_unclassified_section":["17 PATIENT COUNSELING INFORMATION Myopathy and Rhabdomyolysis Advise patients that pitavastatin tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions ( 5.1 )]. Hepatic Dysfunction Inform patients that pitavastatin tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice [see Warnings and Precautions ( 5.3 )]. Increases in HbA1c and Fasting Serum Glucose Levels Inform patients that increases in HbA1c and fasting serum glucose levels may occur with pitavastatin tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices [see Warnings and Precautions ( 5.4 )]. Pregnancy Advise pregnant patients and patients who become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if pitavastatin tablets should discontinued [see Use in Specific Populations ( 8.1 )]. Lactation Advise patients that breastfeed is not recommended during treatment with pitavastatin tablets [see Use in Specific Populations ( 8.2 )]. Manufactured for: AvKARE Pulaski, TN 38478 Mfg. Rev. 12/23 AV 12/23 (M) To request additional information or if you have questions concerning pitavastatin tablets please call AvKARE at 1-855-361-3993."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Take orally once daily with or without food at the same time each day ( 2.1 ). For patients requiring a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment. ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiation of pitavastatin tablets, and adjust the dosage if necessary. ( 2.1 ). Recommended dosage is 2 mg to 4 mg once daily. Maximum recommended dosage is 4 mg once daily. ( 2.2 ) Recommended starting dosage for patients with moderate and severe renal impairment and end-stage renal disease on hemodialysis is 1 mg once daily. Maximum recommended dosage is 2 mg once daily. ( 2.3 ) See full prescribing information for pitavastatin tablets dosage modifications due to drug interactions. ( 2.4 ) 2.1 Important Dosage and Administration Information Take pitavastatin tablets orally once daily with or without food at the same time each day. For patients requiring a high-intensity statin or are unable to achieve their LDL-C goal receiving pitavastatin tablets 4 mg daily, prescribe alternative LDL-C-lowering treatment. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiation of pitavastatin tablets, and adjust the dosage if necessary. 2.2 Recommended Dosage for Adults The recommended dosage range of pitavastatin tablets is 2 mg to 4 mg daily. The maximum recommended dosage is pitavastatin tablets 4 mg once daily. 2.3 Recommended Dosage in Patients with Renal Impairment The recommended starting dose for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30 – 59 mL/minute/1.73 m 2 and 15 – 29 mL/minute/1.73 m 2 , respectively) and patients with end-stage renal disease receiving hemodialysis is pitavastatin tablets 1 mg once daily. The maximum recommended dose for these patients is pitavastatin tablets 2 mg once daily [see Use in Specific Populations ( 8.6 )]. There are no dosage adjustment recommendation for patients with mild renal impairment. 2.4 Pitavastatin Tablets Dosage Adjustments Due to Drug Interactions In patients taking erythromycin, do not exceed pitavastatin tablets 1 mg once daily [see Drug Interactions ( 7 )]. In patients taking rifampin, do not exceed pitavastatin tablets 2 mg once daily [see Drug Interactions ( 7 )]. Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information."],"spl_product_data_elements":["Pitavastatin pitavastatin calcium LACTOSE MONOHYDRATE CELLULOSE, MICROCRYSTALLINE MAGNESIUM OXIDE POVIDONE K30 SODIUM STARCH GLYCOLATE TYPE A POTATO CROSPOVIDONE MAGNESIUM STEARATE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN PITAVASTATIN CALCIUM PITAVASTATIN White Round 58;OP Pitavastatin pitavastatin calcium LACTOSE MONOHYDRATE CELLULOSE, MICROCRYSTALLINE MAGNESIUM OXIDE POVIDONE K30 SODIUM STARCH GLYCOLATE TYPE A POTATO CROSPOVIDONE MAGNESIUM STEARATE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN PITAVASTATIN CALCIUM PITAVASTATIN White Round 59;OP Pitavastatin pitavastatin calcium CELLULOSE, MICROCRYSTALLINE MAGNESIUM OXIDE CROSPOVIDONE MAGNESIUM STEARATE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN LACTOSE MONOHYDRATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE K30 PITAVASTATIN CALCIUM PITAVASTATIN White Round 57;OP"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: 1 mg: White to off-white circular biconvex film-coated tablets. Debossed with the logo “OP” on one side and “57” on the other side of the tablet. 2 mg: White to off-white circular biconvex film-coated tablets. Debossed with the logo “OP” on one side and “58” on the other side of the tablet. 4 mg: White to off-white circular biconvex film-coated tablets. Debossed with the logo “OP” on one side and “59” on the other side of the tablet. Tablets: 1 mg, 2 mg, and 4 mg ( 3 )"],"recent_major_changes_table":["
Contraindications, Pregnancy and Lactation ( 4) Removed 03/2023
Warnings and Precautions, Immune-Mediated Necrotizing Myopathy ( 5.2) 03/2023
"],"clinical_pharmacology_table":["
Coadministered drugDosage regimenChange in AUC* Change in C max*
CyclosporinePitavastatin 2 mg QD for 6 days + cyclosporine 2 mg/kg on Day 6↑ 4.6 fold †↑ 6.6 fold †
ErythromycinPitavastatin 4 mg single dose on Day 4 + erythromycin 500 mg 4 times daily for 6 days↑ 2.8 fold †↑ 3.6 fold †
RifampinPitavastatin 4 mg QD + rifampin 600 mg QD for 5 days↑ 29%↑ 2.0 fold †
AtazanavirPitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days↑ 31%↑ 60%
Darunavir/RitonavirPitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800 mg/100 mg QD on Days 6-16↓ 26%↓ 4%
Lopinavir/RitonavirPitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24↓ 20%↓ 4 %
GemfibrozilPitavastatin 4 mg QD + gemfibrozil 600 mg BID for 7 days↑ 45%↑ 31%
FenofibratePitavastatin 4 mg QD + fenofibrate 160 mg QD for 7 days↑ 18%↑ 11%
EzetimibePitavastatin 2 mg QD + ezetimibe 10 mg for 7 days↓ 2%↓ 0.2%
EnalaprilPitavastatin 4 mg QD + enalapril 20 mg daily for 5 days↑ 6%↓ 7%
DigoxinPitavastatin 4 mg QD + digoxin 0.25 mg for 7 days↑ 4%↓ 9%
Diltiazem LAPitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15↑ 10%↑ 15%
Grapefruit JuicePitavastatin 2 mg single dose on Day 3 + grapefruit juice for 4 days↑ 15%↓ 12%
ItraconazolePitavastatin 4 mg single dose on Day 4 + itraconazole 200 mg daily for 5 days↓ 23%↓ 22%
","
Coadministered drugDosage regimenChange in AUC* Change in C max*
AtazanavirPitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days↑ 6%↑ 13%
DarunavirPitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800 mg/100 mg QD on Days 6-16↑ 3%↑ 6%
LopinavirPitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24↓ 9%↓ 7%
RitonavirPitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9-24↓ 11%↓ 11%
RitonavirPitavastatin 4 mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800 mg/100 mg QD on Days 6-16↑ 8%↑ 2%
EnalaprilPitavastatin 4 mg QD + enalapril 20 mg daily for 5 daysEnalapril↑ 12%↑ 12%
Enalaprilat↓ 1%↓ 1%
WarfarinIndividualized maintenance dose of warfarin (2-7 mg) for 8 days + pitavastatin 4 mg QD for 9 daysR-warfarin↑ 7%↑ 3%
S-warfarin↑ 6%↑ 3%
EzetimibePitavastatin 2 mg QD + ezetimibe 10 mg for 7 days↑ 9%↑ 2%
DigoxinPitavastatin 4 mg QD + digoxin 0.25 mg for 7 days↓ 3%↓ 4%
Diltiazem LAPitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15↓ 2%↓ 7%
RifampinPitavastatin 4 mg QD + rifampin 600 mg QD for 5 days↓ 15%↓ 18%
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. ( 8.1 ) Lactation: Breastfeeding not recommended during treatment with pitavastatin tablets See 17 for PATIENT COUNSELING INFORMATION. Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. 8.1 Pregnancy Risk Summary Discontinue pitavastatin tablets when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Pitavastatin tablets decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, pitavastatin may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology ( 12.1 )]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with statin use in pregnant women are insufficient to determine if there is a drug associated risk of miscarriage [see Data]. In animal reproduction studies, no embryo-fetal toxicity or congenital malformations were observed in pregnant rats and rabbits orally administered pitavastatin during the period of organogenesis at doses which were 22 and 4 times, respectively, the human exposure at the maximum recommended human dosage (MRHD) of 4 mg, based on AUC [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Human Data A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births. Animal Data Embryo-fetal developmental studies were conducted in pregnant rats administered 3, 10, 30 mg/kg/day pitavastatin by oral gavage during organogenesis (gestation days 7-17). No adverse effects were observed at 3 mg/kg/day, systemic exposures 22 times human systemic exposure at 4 mg/day based on AUC. Embryo-fetal developmental studies were conducted in pregnant rabbits administered 0.1, 0.3, 1 mg/kg/day pitavastatin by oral gavage during the period of fetal organogenesis(gestation days 6-18). Maternal toxicity consisting of reduced body weight and abortion was observed at all doses tested (4 times human systemic exposure at 4 mg/day based on AUC). In perinatal/postnatal studies in pregnant rats given oral gavage doses of pitavastatin at 0.1, 0.3, 1, 3, 10, 30 mg/kg/day from organogenesis through weaning (gestation day 17 to lactation day 21), maternal toxicity consisting of mortality at ≥0.3 mg/kg/day and impaired lactation at all doses contributed to the decreased survival of neonates in all dose groups (0.1 mg/kg/day represents approximately 1 time human systemic exposure at 4 mg/day dose based on AUC). Reproductive toxicity studies have shown that pitavastatin crosses the placenta in rats and is found in fetal tissues at ≤36% of maternal plasma concentrations following a single dose of 1 mg/kg/day during gestation (at the end of organogenesis). 8.2 Lactation Risk Summary There is no available information about the presence of pitavastatin in human or animal milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. However, it has been shown that another drug in this class passes into human milk.Statins, including pitavastatin tablets, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. Because of the potential for serious adverse reactions in a breastfed infant, based upon the mechanism of action, advise patients that breastfeeding is not recommended during treatment with pitavastatin tablets. [see Use in Specific Populations ( 8.1 ), Clinical Pharmacology ( 12.1 )] 8.4 Pediatric Use The safety and effectiveness of pitavastatin tablets have not been established in pediatric patients younger than 8 years of age with HeFH or in pediatric patients with other types of hyperlipidemia (other than HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. 8.5 Geriatric Use In controlled clinical studies, 1,209 (43%) patients were 65 years and older. No significant differences in efficacy or safety were observed between geriatric patients and younger patients. Advanced age (≥65 years) is a risk factor for pitavastatin tablets-associated myopathy and rhabdomyolysis. Dose selection for a geriatric patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving pitavastatin tablets for the increased risk of myopathy [see Warnings and Precautions ( 5.1 )]. 8.6 Renal Impairment Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. Due to the risk of myopathy, a dosage modification of pitavastatin tablets is recommended for patients with moderate and severe renal impairment (estimated glomerular filtration rate 30 – 59 mL/min/1.73 m 2 and 15 – 29 mL/min/1.73 m 2 , respectively), as well as end-stage renal disease receiving hemodialysis. [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.1 ), Clinical Pharmacology ( 12.3 )]. 8.7 Hepatic Impairment Pitavastatin is contraindicated in patients with active liver failure or decompensated cirrhosis [see Contraindications ( 4 ), Warnings and Precautions ( 5.3 )]."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 1 2 3"]},"tags":[{"label":"HMG-CoA Reductase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","category":"target"},{"label":"HMGCR","category":"gene"},{"label":"NR4A2","category":"gene"},{"label":"RXRA","category":"gene"},{"label":"C10AA08","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Familial hypercholesterolemia","category":"indication"},{"label":"Hypercholesterolemia","category":"indication"},{"label":"Mixed hyperlipidemia","category":"indication"},{"label":"Kowa Co","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anticholesteremic Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"MYALGIA","source":"FDA FAERS","actionTaken":"807 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"617 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"550 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"540 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"526 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"504 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"495 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"456 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"436 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"426 reports"}],"drugInteractions":[{"url":"/drug/choline-fenofibrate","drug":"choline fenofibrate","action":"Monitor closely","effect":"May interact with Fenofibric Acid","source":"DrugCentral","drugSlug":"choline-fenofibrate"},{"url":"/drug/ciclosporin","drug":"ciclosporin","action":"Avoid combination","effect":"May interact with Cyclosporine","source":"DrugCentral","drugSlug":"ciclosporin"},{"url":"/drug/clarithromycin","drug":"clarithromycin","action":"Avoid combination","effect":"May interact with Clarithromycin","source":"DrugCentral","drugSlug":"clarithromycin"},{"url":"/drug/clofibrate","drug":"clofibrate","action":"Monitor closely","effect":"May interact with Clofibrate","source":"DrugCentral","drugSlug":"clofibrate"},{"url":"/drug/erythromycin","drug":"erythromycin","action":"Avoid combination","effect":"May interact with Erythromycin","source":"DrugCentral","drugSlug":"erythromycin"},{"url":"/drug/fenofibrate","drug":"fenofibrate","action":"Monitor closely","effect":"May interact with Fenofibrate","source":"DrugCentral","drugSlug":"fenofibrate"},{"url":"/drug/gemfibrozil","drug":"gemfibrozil","action":"Monitor closely","effect":"May interact with Gemfibrozil","source":"DrugCentral","drugSlug":"gemfibrozil"},{"url":"/drug/lopinavir","drug":"lopinavir","action":"Avoid combination","effect":"May interact with Lopinavir","source":"DrugCentral","drugSlug":"lopinavir"},{"url":"/drug/nicotinamide","drug":"nicotinamide","action":"Monitor closely","effect":"May interact with Niacinamide","source":"DrugCentral","drugSlug":"nicotinamide"},{"url":"/drug/nicotinic-acid","drug":"nicotinic acid","action":"Monitor closely","effect":"May interact with Niacin","source":"DrugCentral","drugSlug":"nicotinic-acid"},{"url":"/drug/nicotinyl-alcohol","drug":"nicotinyl alcohol","action":"Monitor closely","effect":"May interact with Nicotinyl Alcohol Tartrate","source":"DrugCentral","drugSlug":"nicotinyl-alcohol"},{"url":"/drug/rifampicin","drug":"rifampicin","action":"Avoid combination","effect":"May interact with Rifampin","source":"DrugCentral","drugSlug":"rifampicin"},{"url":"/drug/ritonavir","drug":"ritonavir","action":"Avoid combination","effect":"May interact with Ritonavir","source":"DrugCentral","drugSlug":"ritonavir"},{"url":"/drug/troleandomycin","drug":"troleandomycin","action":"Avoid combination","effect":"May interact with Troleandomycin","source":"DrugCentral","drugSlug":"troleandomycin"}],"commonSideEffects":[{"effect":"Myalgia","drugRate":"1.9%","_validated":true,"placeboRate":"1.4%"},{"effect":"Myalgia","drugRate":"2.8%","_validated":true,"placeboRate":""},{"effect":"Myalgia","drugRate":"3.1%","_validated":true,"placeboRate":""},{"effect":"Constipation","drugRate":"3.6%","_validated":true,"placeboRate":"1.9%"},{"effect":"Constipation","drugRate":"1.5%","_validated":true,"placeboRate":""},{"effect":"Constipation","drugRate":"2.2%","_validated":true,"placeboRate":""},{"effect":"Diarrhea","drugRate":"2.6%","_validated":true,"placeboRate":"1.9%"},{"effect":"Diarrhea","drugRate":"1.5%","_validated":true,"placeboRate":""},{"effect":"Diarrhea","drugRate":"1.9%","_validated":true,"placeboRate":""},{"effect":"Back Pain","drugRate":"3.9%","_validated":true,"placeboRate":"2.9%"},{"effect":"Back Pain","drugRate":"1.8%","_validated":true,"placeboRate":""},{"effect":"Back Pain","drugRate":"1.4%","_validated":true,"placeboRate":""},{"effect":"Pain in extremity","drugRate":"2.3%","_validated":true,"placeboRate":"1.9%"},{"effect":"Pain in extremity","drugRate":"0.6%","_validated":true,"placeboRate":""},{"effect":"Pain in extremity","drugRate":"0.9%","_validated":true,"placeboRate":""}],"contraindications":["Acute infectious disease","Breastfeeding (mother)","Dehydration","Disease of liver","Disorder of muscle","Hemorrhagic cerebral infarction","Hypothyroidism","Impaired renal function disorder","Liver function tests abnormal","Low blood pressure","Pregnancy, function","Rhabdomyolysis","Sepsis syndrome","Surgical procedure","Traumatic injury","Uncontrolled Epilepsy"],"specialPopulations":{"Pregnancy":"ZYPITAMAG is contraindicated for use in pregnant women since safety in pregnant women has not been established and there is no apparent benefit to therapy with pitavastatin during pregnancy. Because HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, ZYPITAMAG may cause fetal harm when administered to pregnant women. ZYPITAMAG should be discontinued as soon as pregnancy is recognized.","Geriatric use":"In controlled clinical studies, 1,209 (43%) patients were 65 years and older. No significant differences in efficacy or safety were observed between geriatric patients and younger patients. Advanced age (>=65 years) is a risk factor for myopathy and rhabdomyolysis. In general, dose selection for geriatric patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy and rhabdomyolysis.","Paediatric use":"The safety and effectiveness of ZYPITAMAG have not been established in pediatric patients younger than 8 years of age with heterozygous familial hypercholesterolemia (HeFH) or in pediatric patients with other types of hyperlipidemia (other than HeFH)."},"discontinuationRates":[{"trial":"controlled clinical studies and their open-label extensions","drugArm":"3.9% (1 mg)","placeboArm":"","commonReason":""},{"trial":"controlled clinical studies and their open-label extensions","drugArm":"3.3% (2 mg)","placeboArm":"","commonReason":""},{"trial":"controlled clinical studies and their open-label extensions","drugArm":"3.7% (4 mg)","placeboArm":"","commonReason":""}],"seriousAdverseEvents":[{"event":"elevated creatine phosphokinase","detail":"led to treatment discontinuation","severity":"serious","incidence":"0.6% on 4 mg"},{"event":"myalgia","detail":"led to treatment discontinuation","severity":"serious","incidence":"0.5% on 4 mg"}]},"trials":[],"aliases":[],"company":"Kowa Co","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-17","unitCost":"$2.0482/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$748","description":"PITAVASTATIN 2 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PITAVASTATIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T04:08:02.031008+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T04:08:08.533164+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T04:08:00.670586+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PITAVASTATIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T04:08:09.340489+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:07:59.272193+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:07:59.272257+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T04:08:10.884270+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201753/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T04:08:09.810965+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following serious adverse reactions are discussed in other sections of the labeling: Myopathy and Rhabdomyolysis [see Warnings and Precautions ( 5.1 )] Immune-Mediated Necrotizing Myopathy [see Warning and Precautions ( 5.2 )] Hepatic Dysfunction [see Warning and Precautions ( 5.3 )] Increases in HbA1c and Fasting Serum Glucose Levels [see Warning and Precautions ( 5.4 )]. The most frequent adverse reactions (rate ≥2%) were myalgia, constipation, back pain, diarrhea, and ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:08:45.530714+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA205932","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T04:07:59.272267+00:00"}},"allNames":"livalo","offLabel":[],"synonyms":["nisvastatin","itavastatin","pitavastatin calcium hydrate","pitavastatin","pitavastatin calcium","livalo"],"timeline":[{"date":"2009-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from KOWA CO to Kowa Co"},{"date":"2009-08-03","type":"positive","source":"DrugCentral","milestone":"FDA approval (Kowa Co)"},{"date":"2015-06-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Kowa Company, Ltd.)"},{"date":"2024-04-30","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 7 manufacturers approved"}],"aiSummary":"Livalo (Pitavastatin) is a small molecule HMG-CoA Reductase Inhibitor developed by Kowa Co, targeting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It was FDA approved in 2009 for the treatment of Familial hypercholesterolemia, Hypercholesterolemia, and Mixed hyperlipidemia. Livalo is now off-patent with 8 generic manufacturers available. The drug has a half-life of 4.6 hours and bioavailability of 80%. Key safety considerations include monitoring liver function and muscle damage risk.","approvals":[{"date":"2009-08-03","orphan":false,"company":"KOWA CO","regulator":"FDA"},{"date":"2015-06-26","orphan":false,"company":"Kowa Company, Ltd.","regulator":"PMDA"}],"brandName":"Livalo","ecosystem":[{"indication":"Familial hypercholesterolemia","otherDrugs":[],"globalPrevalence":390000000},{"indication":"Hypercholesterolemia","otherDrugs":[{"name":"alirocumab","slug":"alirocumab","company":"Sanofi Aventis"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"cerivastatin","slug":"cerivastatin","company":"Bayer Pharms"},{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"}],"globalPrevalence":390000000},{"indication":"Mixed hyperlipidemia","otherDrugs":[{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"cerivastatin","slug":"cerivastatin","company":"Bayer Pharms"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"ezetimibe","slug":"ezetimibe","company":"Msd Intl Gmbh"}],"globalPrevalence":390000000}],"mechanism":{"target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","novelty":"Follow-on","targets":[{"gene":"HMGCR","source":"DrugCentral","target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","protein":"3-hydroxy-3-methylglutaryl-coenzyme A reductase"},{"gene":"NR4A2","source":"DrugCentral","target":"Nuclear receptor subfamily 4 group A member 2","protein":"Nuclear receptor subfamily 4 group A member 2"},{"gene":"RXRA","source":"DrugCentral","target":"Retinoic acid receptor RXR-alpha","protein":"Retinoic acid receptor RXR-alpha"}],"moaClass":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","modality":"Small Molecule","drugClass":"HMG-CoA Reductase Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Pitavastatin inhibits the enzyme HMG-CoA reductase, a key rate-limiting step in the cholesterol biosynthesis pathway, thereby reducing the hepatic production of cholesterol and increasing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream."},"commercial":{"launchDate":"2009","_launchSource":"DrugCentral (FDA 2009-08-03, KOWA CO)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2214","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PITAVASTATIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PITAVASTATIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:25:59.360067","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:08:48.736076+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"simvastatin","drugSlug":"simvastatin","fdaApproval":"1991-12-23","patentExpiry":"Feb 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lovastatin","drugSlug":"lovastatin","fdaApproval":"1987-08-31","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pravastatin","drugSlug":"pravastatin","fdaApproval":"1991-10-31","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fluvastatin","drugSlug":"fluvastatin","fdaApproval":"1993-12-31","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"atorvastatin","drugSlug":"atorvastatin","fdaApproval":"1996-12-17","patentExpiry":"Jun 7, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cerivastatin","drugSlug":"cerivastatin","fdaApproval":"1997-06-26","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"rosuvastatin","drugSlug":"rosuvastatin","fdaApproval":"2003-08-12","patentExpiry":"Feb 12, 2036","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"pitavastatin","indications":{"approved":[{"name":"Familial hypercholesterolemia","source":"DrugCentral","snomedId":398036000,"regulator":"FDA","usPrevalence":86000000,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO Global Health Estimates, 2023"},{"name":"Hypercholesterolemia","source":"DrugCentral","snomedId":13644009,"regulator":"FDA","usPrevalence":86000000,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO Global Health Estimates, 2023"},{"name":"Mixed hyperlipidemia","source":"DrugCentral","snomedId":267434003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Kowa Co","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"simvastatin","brandName":"simvastatin","genericName":"simvastatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"lovastatin","brandName":"lovastatin","genericName":"lovastatin","approvalYear":"1987","relationship":"same-class"},{"drugId":"pravastatin","brandName":"pravastatin","genericName":"pravastatin","approvalYear":"1991","relationship":"same-class"},{"drugId":"fluvastatin","brandName":"fluvastatin","genericName":"fluvastatin","approvalYear":"1993","relationship":"same-class"},{"drugId":"atorvastatin","brandName":"atorvastatin","genericName":"atorvastatin","approvalYear":"1996","relationship":"same-class"},{"drugId":"cerivastatin","brandName":"cerivastatin","genericName":"cerivastatin","approvalYear":"1997","relationship":"same-class"},{"drugId":"rosuvastatin","brandName":"rosuvastatin","genericName":"rosuvastatin","approvalYear":"2003","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07460960","phase":"PHASE2","title":"TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","status":"RECRUITING","sponsor":"Lomonosov Moscow State University Medical Research and Educational Center","startDate":"2026-03-05","conditions":["Erectile Dysfunction Due to Arterial Disease","Atheroscleroses","Erectile Disfunction","Endothelial Dysfunction","Androgen Profile","Testosterone"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT06982131","phase":"PHASE1","title":"A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-04","conditions":["Overweight","Obesity"],"enrollment":40,"completionDate":"2026-12-04"},{"nctId":"NCT07445542","phase":"","title":"Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2021-12-18","conditions":["Hypercholesterolemia"],"enrollment":6927,"completionDate":"2025-05-13"},{"nctId":"NCT07442630","phase":"PHASE4","title":"Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides","status":"ACTIVE_NOT_RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2023-08-21","conditions":["Hypercholesterolemia"],"enrollment":88,"completionDate":"2026-11-30"},{"nctId":"NCT06553157","phase":"PHASE1,PHASE2","title":"Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Minia University","startDate":"2024-09-01","conditions":["Solid Tumors","Ototoxicity"],"enrollment":56,"completionDate":"2025-10-01"},{"nctId":"NCT07351565","phase":"PHASE1","title":"Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chang Chen","startDate":"2026-01-10","conditions":["Non-Small Cell Lung Cancer"],"enrollment":22,"completionDate":"2026-12-31"},{"nctId":"NCT07307989","phase":"PHASE2","title":"Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-08-01","conditions":["Ischemic Stroke","Hypercholesteremia"],"enrollment":300,"completionDate":"2029-07-31"},{"nctId":"NCT06501443","phase":"PHASE4","title":"LATAM LOWERS LDL-C","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-11","conditions":["Hypercholesterolaemia"],"enrollment":520,"completionDate":"2026-11-29"},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":["HIV Infections","Weight Gain"],"enrollment":300,"completionDate":"2026-12"},{"nctId":"NCT06813924","phase":"PHASE1","title":"A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-02-06","conditions":["Healthy Volunteers Sickle Cell Disease, Thalassemia"],"enrollment":37,"completionDate":"2025-05-27"},{"nctId":"NCT06314919","phase":"","title":"A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2024-03-15","conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemia"],"enrollment":8606,"completionDate":"2026-06"},{"nctId":"NCT04512105","phase":"PHASE1","title":"Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2020-12-02","conditions":["Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","AML, Adult","CLL","CLL, Relapsed","CLL, Refractory"],"enrollment":6,"completionDate":"2025-02-05"},{"nctId":"NCT01764178","phase":"PHASE1","title":"To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2013-01-22","conditions":["Hyperlipidemia","Hypertension"],"enrollment":52,"completionDate":"2013-12-27"},{"nctId":"NCT02344290","phase":"PHASE3","title":"Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-03-26","conditions":["HIV","Cardiovascular Diseases"],"enrollment":7769,"completionDate":"2023-08-21"},{"nctId":"NCT07083206","phase":"","title":"A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe","status":"RECRUITING","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2025-07-29","conditions":["Hypercholesterolemia","Dyslipidemias"],"enrollment":4500,"completionDate":"2029-01"},{"nctId":"NCT06722521","phase":"PHASE4","title":"GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary Calcification","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-09","conditions":["Primary Prevention","Vascular Calcification"],"enrollment":7435,"completionDate":"2032-10-31"},{"nctId":"NCT06767774","phase":"PHASE4","title":"Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","status":"RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2025-04-25","conditions":["ASCVD","Diabetes","Statin"],"enrollment":2000,"completionDate":"2030-01-31"},{"nctId":"NCT06808646","phase":"PHASE1","title":"A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2025-01-17","conditions":["Drug-drug Interaction Study"],"enrollment":12,"completionDate":"2025-02-25"},{"nctId":"NCT06858982","phase":"","title":"PMMHRI-Pitavastatin Registry","status":"RECRUITING","sponsor":"Polish Mother Memorial Hospital Research Institute","startDate":"2024-06-01","conditions":["Hypercholesterolemia"],"enrollment":500,"completionDate":"2028-12"},{"nctId":"NCT02888327","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872","status":"COMPLETED","sponsor":"Alios Biopharma Inc.","startDate":"2016-07-31","conditions":["Influenza in Humans"],"enrollment":68,"completionDate":"2017-05-30"},{"nctId":"NCT05537948","phase":"PHASE4","title":"Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-10-01","conditions":["Dyslipidemias","Hyperlipidemias","Liver Transplant Disorder","Immunosuppression","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Statins"],"enrollment":59,"completionDate":"2025-01-31"},{"nctId":"NCT03070223","phase":"PHASE3","title":"PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-03-14","conditions":["HIV-1 Infection"],"enrollment":602,"completionDate":"2023-08-21"},{"nctId":"NCT05977738","phase":"EARLY_PHASE1","title":"Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin","status":"COMPLETED","sponsor":"C.Dirven","startDate":"2024-01-18","conditions":["Glioblastoma Multiforme, Adult","Recurrent Glioblastoma"],"enrollment":12,"completionDate":"2024-07-19"},{"nctId":"NCT02956590","phase":"PHASE3","title":"Dyslipidemia of Obesity Intervention in Teens","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2018-05-01","conditions":["Dyslipidemia","Obesity"],"enrollment":122,"completionDate":"2023-06-30"},{"nctId":"NCT05285085","phase":"","title":"Real World Evidence Study of Statin Use in Brazil","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2021-11-19","conditions":["Cardiovascular Diseases","Myocardial Infarction","Stroke","Hypertension","Diabetes Mellitus","Dyslipidemias"],"enrollment":2133900,"completionDate":"2021-12-15"},{"nctId":"NCT06359353","phase":"PHASE4","title":"Effect of Pitavastatin on Bone","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2019-04-08","conditions":["Osteoporosis, Osteopenia","Hypercholesterolemia","Menopausal Osteoporosis"],"enrollment":70,"completionDate":"2023-12-19"},{"nctId":"NCT06273215","phase":"PHASE4","title":"Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-05","conditions":["Diabetes"],"enrollment":48,"completionDate":"2025-12-31"},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":["Cardiovascular Diseases","Dyslipidemias","Statin Adverse Reaction","Pharmacogenic Myopathy"],"enrollment":216,"completionDate":"2025-03-04"},{"nctId":"NCT06001047","phase":"NA","title":"Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV","status":"RECRUITING","sponsor":"Xi'an No.3 Hospital","startDate":"2023-11-01","conditions":["Benign Paroxysmal Positional Vertigo"],"enrollment":120,"completionDate":"2026-11-01"},{"nctId":"NCT04289662","phase":"PHASE3","title":"K-924 Phase III Long Term Study","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2020-03-23","conditions":["Hypercholesterolemia"],"enrollment":110,"completionDate":"2021-08-07"},{"nctId":"NCT04289649","phase":"PHASE3","title":"K-924 Phase III Confirmatory Study","status":"COMPLETED","sponsor":"Kowa Company, Ltd.","startDate":"2020-04-02","conditions":["Hypercholesterolemia"],"enrollment":293,"completionDate":"2020-11-21"},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":["Acute Coronary Syndrome","Non ST Segment Elevation Acute Coronary Syndrome"],"enrollment":3684,"completionDate":"2027-11-01"},{"nctId":"NCT00242944","phase":"PHASE4","title":"Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2005-11","conditions":["Coronary Disease","Hypercholesterolemia"],"enrollment":307,"completionDate":"2008-03"},{"nctId":"NCT01710007","phase":"PHASE3","title":"Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2011-11","conditions":["Hypercholesterolemia"],"enrollment":202,"completionDate":"2012-11"},{"nctId":"NCT05705804","phase":"NA","title":"Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2023-06-13","conditions":["Dyslipidemias","Atherosclerotic Cardiovascular Disease"],"enrollment":250,"completionDate":"2025-04"},{"nctId":"NCT05747768","phase":"PHASE4","title":"A Clinical Study to Evaluate the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Healthy Volunteers and Renal Impairment Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-07-15","conditions":["Chronic Kidney Disease"],"enrollment":60,"completionDate":"2024-12-31"},{"nctId":"NCT05334108","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2022-04-26","conditions":["Drug Interaction"],"enrollment":56,"completionDate":"2022-08-26"},{"nctId":"NCT04643093","phase":"PHASE3","title":"Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2020-08-01","conditions":["Primary Hypercholesterolemia","Mixed Dyslipidemias"],"enrollment":390,"completionDate":"2021-10-05"},{"nctId":"NCT04945122","phase":"PHASE4","title":"Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in AMI Patients With Abnormal Glucose Metabolism","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2015-10-01","conditions":["Acute Myocardial Infarction","Glucose Metabolism Disorders"],"enrollment":900,"completionDate":"2023-12-31"},{"nctId":"NCT01166633","phase":"PHASE4","title":"Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-06","conditions":["Hypercholesterolemia"],"enrollment":200,"completionDate":"2011-02"},{"nctId":"NCT00653913","phase":"PHASE1","title":"Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":["Hypercholesterolemia"],"enrollment":18,"completionDate":"2004-09"},{"nctId":"NCT04584736","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-06-11","conditions":["Primary Hypercholesterolemia"],"enrollment":283,"completionDate":"2020-10-12"},{"nctId":"NCT02863185","phase":"PHASE4","title":"Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2016-05-01","conditions":["Chronic Kidney Disease"],"enrollment":45,"completionDate":"2020-12-31"},{"nctId":"NCT00846118","phase":"NA","title":"Differential Intervention Trial by Standard Therapy Versus Pitavastatin in Patients With Chronic Hemodialysis (DIALYSIS)","status":"TERMINATED","sponsor":"Chieko Hamada","startDate":"2009-02-01","conditions":["Cardiovascular Disease"],"enrollment":905,"completionDate":"2014-09-30"},{"nctId":"NCT01057433","phase":"PHASE4","title":"Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2010-01","conditions":["Healthy Volunteers"],"enrollment":24,"completionDate":"2010-12"},{"nctId":"NCT04764851","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates","status":"TERMINATED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-02-18","conditions":["Drug-Interactions"],"enrollment":30,"completionDate":"2021-05-07"},{"nctId":"NCT01042730","phase":"NA","title":"Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2010-02","conditions":["Coronary Artery Disease"],"enrollment":13054,"completionDate":"2017-11"},{"nctId":"NCT02670434","phase":"PHASE3","title":"Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia","status":"WITHDRAWN","sponsor":"Kowa Research Institute, Inc.","startDate":"2016-01","conditions":["Hyperlipidemia","Dyslipidemia"],"enrollment":0,"completionDate":"2017-10"},{"nctId":"NCT02799758","phase":"PHASE3","title":"Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia","status":"WITHDRAWN","sponsor":"Kowa Research Institute, Inc.","startDate":"2016-02","conditions":["Hyperlipidemia","Dyslipidemia"],"enrollment":0,"completionDate":"2017-11"},{"nctId":"NCT04402112","phase":"","title":"Efficacy and Safety of Pitavastatin in a Real-world Setting","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2012-04-02","conditions":["Hypercholesterolemia"],"enrollment":28343,"completionDate":"2017-08-01"},{"nctId":"NCT04270344","phase":"","title":"The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment","status":"UNKNOWN","sponsor":"JW Pharmaceutical","startDate":"2018-07-01","conditions":["Hypercholesterolemia"],"enrollment":905,"completionDate":"2022-06-30"},{"nctId":"NCT04829149","phase":"","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2016-06-14","conditions":["Dyslipidemias"],"enrollment":5717,"completionDate":"2019-08-29"},{"nctId":"NCT04705909","phase":"PHASE2,PHASE3","title":"Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-01-15","conditions":["Breast Cancer"],"enrollment":60,"completionDate":"2021-12-15"},{"nctId":"NCT02545231","phase":"PHASE4","title":"Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2013-02","conditions":["Atherosclerosis","Neointima","Angina"],"enrollment":1000,"completionDate":"2020-08"},{"nctId":"NCT03730038","phase":"NA","title":"Effects of Pitavastatin Treatments on the Plasma Lgi3 Level in the Patients With Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2019-02-18","conditions":["Dyslipidemias"],"enrollment":50,"completionDate":"2020-02-13"},{"nctId":"NCT01695954","phase":"PHASE1","title":"Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-05","conditions":["Hyperlipidemia","HIV"],"enrollment":34,"completionDate":"2013-01"},{"nctId":"NCT03717064","phase":"PHASE1","title":"A Study to Investigate the Effect of RO7049389 on the Pharmacokinetics of Pitavastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-11-07","conditions":["Healthy Volunteers"],"enrollment":18,"completionDate":"2018-12-17"},{"nctId":"NCT03311841","phase":"PHASE1","title":"Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-01","conditions":["Renal Insufficiency"],"enrollment":32,"completionDate":"2018-08-02"},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":["Hypercholesterolemia"],"enrollment":527,"completionDate":"2014-06"},{"nctId":"NCT00889226","phase":"PHASE4","title":"Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-04","conditions":["Hypercholesterolemia With Type2DM"],"enrollment":161,"completionDate":"2010-01"},{"nctId":"NCT02743260","phase":"PHASE4","title":"Drug Transporter Interaction Study PHENTRA_2015_KPUK","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2016-04","conditions":["Healthy"],"enrollment":24,"completionDate":"2017-12"},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":["Hypertension","Dyslipidemias"],"enrollment":150,"completionDate":"2018-12-20"},{"nctId":"NCT02290106","phase":"NA","title":"Effects of Pitavastatin on Insulin Sensitivity and Liver Fat","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-03-02","conditions":["Obesity","Fatty Liver, Nonalcoholic"],"enrollment":50,"completionDate":"2018-04-30"},{"nctId":"NCT03532620","phase":"PHASE4","title":"China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension","status":"UNKNOWN","sponsor":"Jun Tao","startDate":"2018-08-09","conditions":["Prediabetic State","Hypertension","Dyslipidemias"],"enrollment":396,"completionDate":"2020-09"},{"nctId":"NCT03606824","phase":"NA","title":"Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)","status":"UNKNOWN","sponsor":"Shaochun.Li","startDate":"2019-03-25","conditions":["Dyslipidemia","Subclinical hypothyroïdism","Statin","ASCVD"],"enrollment":248,"completionDate":"2020-05-31"},{"nctId":"NCT00723398","phase":"NA","title":"Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-03","conditions":["Breast Cancer"],"enrollment":266,"completionDate":"2015-04"},{"nctId":"NCT03618797","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of Pitavastatin/Fenofibrate in Complex-dyslipidemia","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2015-11","conditions":["Complex-dyslipidemia"],"enrollment":347,"completionDate":"2018-05"},{"nctId":"NCT01767610","phase":"PHASE1","title":"Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2013-01","conditions":["Healthy Male Volunteers"],"enrollment":24,"completionDate":"2013-07"},{"nctId":"NCT02250976","phase":"PHASE1","title":"The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2014-09","conditions":["Healthy Male Volunteers"],"enrollment":41,"completionDate":"2014-10"},{"nctId":"NCT02056847","phase":"PHASE4","title":"to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2013-09","conditions":["HbA1c Level Associated With Lipid Compositions"],"enrollment":313,"completionDate":"2017-05"},{"nctId":"NCT03418974","phase":"PHASE4","title":"Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2017-11-01","conditions":["Dyslipidemias"],"enrollment":10000,"completionDate":"2021-12-31"},{"nctId":"NCT02940366","phase":"PHASE4","title":"Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-12-01","conditions":["Metabolic Syndrome"],"enrollment":500,"completionDate":"2019-11-30"},{"nctId":"NCT01660191","phase":"PHASE4","title":"A Study Comparing CoQ10 Levels While Taking 3 Different Statins","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2011-12","conditions":["Hypercholesterolemia"],"enrollment":134,"completionDate":"2013-10"},{"nctId":"NCT02144922","phase":"PHASE4","title":"Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2014-05","conditions":["Hypertension","Cardiovascular Risk"],"enrollment":85,"completionDate":"2016-10"},{"nctId":"NCT02442700","phase":"PHASE4","title":"Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2014-05","conditions":["HIV","Dyslipidemia"],"enrollment":24,"completionDate":"2015-01"},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":["Hypercholesterolemia"],"enrollment":216,"completionDate":"2015-09"},{"nctId":"NCT01502904","phase":"PHASE4","title":"Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-07","conditions":["Stable Angina or Acute Coronary Syndrome Considered for Percutaneous Coronary Intervention With Dyslipidemia or Hypertension"],"enrollment":120,"completionDate":"2015-06"},{"nctId":"NCT02595268","phase":"PHASE1","title":"A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11","conditions":["Healthy"],"enrollment":14,"completionDate":"2016-01"},{"nctId":"NCT02634034","phase":"PHASE1","title":"A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2015-12","conditions":["Hyperlipidemia"],"enrollment":18,"completionDate":"2015-12"},{"nctId":"NCT01265706","phase":"","title":"Livalo Acute Myocardial Infarction Study (LAMIS)","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2010-07","conditions":["Acute Myocardial Infarction"],"enrollment":1000,"completionDate":"2014-12"},{"nctId":"NCT01402843","phase":"PHASE3","title":"Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2011-06","conditions":["Hypertension","Dyslipidemia"],"enrollment":150,"completionDate":"2013-01"},{"nctId":"NCT00701285","phase":"PHASE4","title":"South Korean Pitavastatin Heart Failure Study","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-07","conditions":["Chronic Heart Failure"],"enrollment":70,"completionDate":"2014-05"},{"nctId":"NCT01301066","phase":"PHASE4","title":"A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2010-12","conditions":["Dyslipidemia"],"enrollment":252,"completionDate":"2013-03"},{"nctId":"NCT00861861","phase":"PHASE4","title":"Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)","status":"COMPLETED","sponsor":"Kumamoto University","startDate":"2008-09","conditions":["Hypercholesterolemia","Coronary Artery Disease"],"enrollment":129,"completionDate":"2013-10"},{"nctId":"NCT00301392","phase":"PHASE4","title":"Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2006-04","conditions":["Diabetes Mellitus","Glucose Intolerance"],"enrollment":1240,"completionDate":"2012-06"},{"nctId":"NCT01595828","phase":"PHASE1","title":"Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome","status":"COMPLETED","sponsor":"Kowa Research Europe","startDate":"2010-10","conditions":["Metabolic Syndrome"],"enrollment":14,"completionDate":"2012-06"},{"nctId":"NCT01871792","phase":"PHASE4","title":"Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2013-06","conditions":["Contrast-induced Nephropathy"],"enrollment":404,"completionDate":"2014-02"},{"nctId":"NCT01648829","phase":"PHASE4","title":"PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2014-01","conditions":["Coronary Artery Disease"],"enrollment":100,"completionDate":"2017-12"},{"nctId":"NCT01406431","phase":"PHASE1","title":"Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2011-08","conditions":["Hyperlipidemia","Hypertension"],"enrollment":48,"completionDate":"2012-10"},{"nctId":"NCT01178853","phase":"PHASE4","title":"Drug-Drug Interaction Study to Assess the Effects of Steady State Pitavastatin 4 mg or Rosuvastatin 40 mg on Steady-State Warfarin in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2010-07","conditions":["Healthy"],"enrollment":48,"completionDate":"2011-04"},{"nctId":"NCT01043094","phase":"PHASE4","title":"Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2009-12","conditions":["Severe Renal Impairment"],"enrollment":16,"completionDate":"2010-12"},{"nctId":"NCT01422369","phase":"PHASE4","title":"Drug-Drug Interaction of Darunavir/Ritonavir on Pitavastatin","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2011-04","conditions":["Healthy"],"enrollment":28,"completionDate":"2011-06"},{"nctId":"NCT01422382","phase":"PHASE4","title":"Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2011-05","conditions":["Healthy"],"enrollment":28,"completionDate":"2011-07"},{"nctId":"NCT00548145","phase":"NA","title":"The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease","status":"TERMINATED","sponsor":"Osaka University","startDate":"2007-11","conditions":["Alzheimer Disease","Hypercholesterolemia"],"enrollment":38,"completionDate":"2012-03"},{"nctId":"NCT01256476","phase":"PHASE4","title":"Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2010-10","conditions":["Primary Dyslipidemia","Mixed Dyslipidemia"],"enrollment":328,"completionDate":"2011-06"},{"nctId":"NCT01223586","phase":"","title":"Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2010-11","conditions":["Statin","Coronary Plaque","Acute Coronary Syndrome","Intravascular Ultrasound","Cardiovascular Events"],"enrollment":238,"completionDate":"2011-05"},{"nctId":"NCT00786734","phase":"PHASE4","title":"Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)","status":"WITHDRAWN","sponsor":"JW Pharmaceutical","startDate":"2008-08","conditions":["Percutaneous Coronary Intervention"],"enrollment":0,"completionDate":"2010-07"},{"nctId":"NCT00640276","phase":"PHASE4","title":"Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2008-04","conditions":["Hypercholesterolemia","Metabolic Syndrome"],"enrollment":187,"completionDate":"2011-06"},{"nctId":"NCT00805714","phase":"","title":"Livalo Acute Myocardial Infarction Study","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2007-04","conditions":["Acute Myocardial Infarction"],"enrollment":1128,"completionDate":"2011-03"},{"nctId":"NCT00716846","phase":"NA","title":"Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers","status":"COMPLETED","sponsor":"Hamamatsu University","startDate":"2006-06","conditions":["Healthy Volunteers"],"enrollment":11,"completionDate":"2008-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Livalo"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"ZYPITAMAG"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000180308","MMSL":"173089","NDDF":"013206","UNII":"M5681Q5F9P","VUID":"4029463","CHEBI":"CHEBI:32020","VANDF":"4029463","INN_ID":"7730","RXNORM":"861612","UMLSCUI":"C1101838","chemblId":"CHEMBL1201753","ChEMBL_ID":"CHEMBL1201753","KEGG_DRUG":"D01862","DRUGBANK_ID":"DB08860","PDB_CHEM_ID":" PV9","PUBCHEM_CID":"5282452","SNOMEDCT_US":"443585001","IUPHAR_LIGAND_ID":"3035","SECONDARY_CAS_RN":"147526-32-7","MESH_SUPPLEMENTAL_RECORD_UI":"C108475"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Kowa Pharmaceuticals America, Inc.","brandName":"Livalo","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2009-","companyName":"Kowa Co","relationship":"Original Developer"},{"period":"2015","companyName":"Kowa Company, Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"4.6 hours","clearance":"5.85 mL/min/kg","bioavailability":"80%","fractionUnbound":"0.005%","volumeOfDistribution":"0.9 L/kg"},"publicationCount":1300,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AA08","allCodes":["C10AA08"]},"biosimilarFilings":[],"originalDeveloper":"Kowa Co","recentPublications":[{"date":"2026","pmid":"41884637","title":"Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort.","journal":"Frontiers in cardiovascular medicine"},{"date":"2026","pmid":"41809229","title":"Statin Induced New-onset Diabetes Mellitus - A Narrative Review.","journal":"Journal of community hospital internal medicine perspectives"},{"date":"2026 Mar 9","pmid":"41803595","title":"EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk.","journal":"Journal of general internal medicine"},{"date":"2026 Feb 5","pmid":"41774493","title":"Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling.","journal":"JCI insight"},{"date":"2026","pmid":"41743539","title":"Three-drug combination therapy to prevent glucocorticoid-associated osteonecrosis in patients with systemic lupus erythematosus: a proof-of-concept study.","journal":"Therapeutic advances in musculoskeletal disease"}],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Amneal Pharms Ny","Aurobindo Pharma","Hetero Labs Ltd V","Lupin Ltd","Mylan","Orient Pharma Co Ltd","Sawai Usa","Zydus Pharms"],"status":"approved","companyName":"Kowa Co","companyId":"kowa-co","modality":"Small molecule","firstApprovalDate":"2009","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-08-03T00:00:00.000Z","mah":"KOWA CO","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-10-31T00:00:00.000Z","mah":"KOWA CO","brand_name_local":null,"application_number":"NDA022363"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2015-06-26T00:00:00.000Z","mah":"Kowa Company, Ltd.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-02-03T00:00:00.000Z","mah":"ORIENT PHARMA CO LTD","brand_name_local":null,"application_number":"ANDA205932"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-04T00:00:00.000Z","mah":"MYLAN","brand_name_local":null,"application_number":"ANDA206070"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-06-11T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":null,"application_number":"ANDA206047"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-22T00:00:00.000Z","mah":"SAWAI USA","brand_name_local":null,"application_number":"ANDA205955"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T04:08:48.736076+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}